KL1333

CAS No. 1800405-30-4

KL1333( NQO1 activator 1 )

Catalog No. M23811 CAS No. 1800405-30-4

KL1333 enhances energy metabolism and mitochondrial dysfunction in MELAS fibroblasts.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 240 In Stock
5MG 182 In Stock
10MG 275 In Stock
25MG 497 In Stock
50MG 732 In Stock
100MG 995 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    KL1333
  • Note
    Research use only, not for human use.
  • Brief Description
    KL1333 enhances energy metabolism and mitochondrial dysfunction in MELAS fibroblasts.
  • Description
    KL1333 enhances energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. Elevated NAD+ levels trigger the activation of SIRT1 and AMPK, and subsequently activates PGC-1α. NQO1 activator 1 is an orally available NAD+ modulator. It reacts with NAD(P)H: NQO1 as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    NQO1 activator 1
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    NADPH
  • Recptor
    NQO1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1800405-30-4
  • Formula Weight
    240.26
  • Molecular Formula
    C14H12N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:245 mg/mL (1019.73 mM; Need ultrasonic)
  • SMILES
    CC(C)c1nc(-c(cccc2)c2C(C2=O)=O)c2[nH]1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Seo KS, et al. KL1333, a Novel NAD+ Modulator, Improves Energy Metabolism and Mitochondrial Dysfunction in MELAS Fibroblasts. Front Neurol. 2018 Jul 5;9:552.
molnova catalog
related products
  • AKR1C3-IN-4

    AKR1C3-IN-4 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC 50 of 0.56 μM. AKR1C3-IN-4 has the potential for castrate resistant prostate cancer (CRPC) research.

  • Cozymasei(NAD+)

    NAD+ is a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.

  • GSK2795039

    GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 decreases apoptosis. GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) (pIC50: 6 in different cell-free assays). GSK2795039 (25 μM; 24 hours) decreases the combinatory effect of FeSO4 and LPS-increased levels of apoptosis.